Pharmacokinetic and biodistribution study following systemic administration of Fospeg - a Pegylated liposomal mTHPC formulation in a murine model

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Pharmacokinetic and biodistribution study following systemic administration of Fospeg - a Pegylated liposomal mTHPC formulation in a murine model. / Xie, Haiyan; Svenmarker, Pontus; Axelsson, Johan; Gräfe, Susanna; Kyriazi, Maria; Bendsöe, Niels; Andersson-Engels, Stefan; Svanberg, Katarina.

I: Journal of Biophotonics, Vol. 8, Nr. 1-2, 2015, s. 142-152.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Xie, Haiyan ; Svenmarker, Pontus ; Axelsson, Johan ; Gräfe, Susanna ; Kyriazi, Maria ; Bendsöe, Niels ; Andersson-Engels, Stefan ; Svanberg, Katarina. / Pharmacokinetic and biodistribution study following systemic administration of Fospeg - a Pegylated liposomal mTHPC formulation in a murine model. I: Journal of Biophotonics. 2015 ; Vol. 8, Nr. 1-2. s. 142-152.

RIS

TY - JOUR

T1 - Pharmacokinetic and biodistribution study following systemic administration of Fospeg - a Pegylated liposomal mTHPC formulation in a murine model

AU - Xie, Haiyan

AU - Svenmarker, Pontus

AU - Axelsson, Johan

AU - Gräfe, Susanna

AU - Kyriazi, Maria

AU - Bendsöe, Niels

AU - Andersson-Engels, Stefan

AU - Svanberg, Katarina

PY - 2015

Y1 - 2015

N2 - Abstract in Undetermined Fospeg® is a newly developed photosensitizer formulation based on meso-tetra(hydroxyphenyl)chlorin (mTHPC), with hydrophilic liposomes to carry the hydrophobic photosensitizer to the target tissue. In this study the pharmacokinetics and biodistribution of Fospeg® were investigated by high performance liquid chromatography at various times (0.5-18 hours) following systemic i.v. administration. As a model an experimental HT29 colon tumor in NMRI nu/nu mice was employed. Our study indicates a higher plasma peak concentration, a longer circulation time and a better tumor-to-skin ratio than those of Foslip®, another liposomal mTHPC formulation. Data from ex vivo tissue fluorescence and reflectance imaging exhibit good correlation with chemical extraction. Our results have shown that optical imaging provides the potential for fluorophore quantification in biological tissues. (© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim).

AB - Abstract in Undetermined Fospeg® is a newly developed photosensitizer formulation based on meso-tetra(hydroxyphenyl)chlorin (mTHPC), with hydrophilic liposomes to carry the hydrophobic photosensitizer to the target tissue. In this study the pharmacokinetics and biodistribution of Fospeg® were investigated by high performance liquid chromatography at various times (0.5-18 hours) following systemic i.v. administration. As a model an experimental HT29 colon tumor in NMRI nu/nu mice was employed. Our study indicates a higher plasma peak concentration, a longer circulation time and a better tumor-to-skin ratio than those of Foslip®, another liposomal mTHPC formulation. Data from ex vivo tissue fluorescence and reflectance imaging exhibit good correlation with chemical extraction. Our results have shown that optical imaging provides the potential for fluorophore quantification in biological tissues. (© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim).

KW - mTHPC

KW - Fospeg

KW - liposomes

KW - pharmacokinetics

KW - biodistribution

KW - high performance liquid chromatography

KW - fluorescence imaging

U2 - 10.1002/jbio.201300133

DO - 10.1002/jbio.201300133

M3 - Article

C2 - 24375973

VL - 8

SP - 142

EP - 152

JO - Journal of Biophotonics

JF - Journal of Biophotonics

SN - 1864-063X

IS - 1-2

ER -